Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 363 clinical trials
Sacituzumab Govitecan in Chinese Patients With mTNBC of at Least 2 Prior Treatments

The purpose of this study is to evaluate the efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (TNBC) who received at least two prior chemotherapy treatments.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

cish
progesterone receptor
HER2
aromatase inhibitor
progesterone
  • 0 views
  • 27 Jan, 2021
  • 49 locations
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer. In summary, the main objectives of AURORA are to better understand the

breast cancer
metastasis
primary tumor
  • 157 views
  • 22 Jan, 2021
  • 60 locations
Randomized Open Label Clinical Study of the Targeted Therapy Palbociclib to Treat Metastatic Breast Cancer

therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.

hysterectomy
fulvestrant
oophorectomy
metastatic cancer
endocrine therapy
  • 544 views
  • 27 Jan, 2021
  • 132 locations
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and …

  • 0 views
  • 26 Jan, 2021
  • 1 location
  • 0 views
  • 01 Mar, 2021
  • 11 locations
  • 0 views
  • 12 Feb, 2021
  • 27 locations
A Study of TAS-120 in Patients With Metastatic Breast Cancer

The purpose of this open-label, nonrandomized, Phase 2 study is to evaluate the efficacy and safety of TAS-120 and TAS-120 + fulvestrant in patients with locally advanced/metastatic breast

progesterone receptor
platelet count
fulvestrant
progesterone
endocrine therapy
  • 17 views
  • 25 Jan, 2021
  • 23 locations
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast

immunological adjuvant
erbb2
fulvestrant
endocrine therapy
immunostimulant
  • 58 views
  • 03 Mar, 2021
  • 88 locations
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual …

  • 139 views
  • 03 Mar, 2021
  • 482 locations